Bintrafusp alfa

必特芙普α

Report date: 2026/05/20 20:02:01

Base Information

Drug NameBintrafusp alfa
Drug Alias NameBintrafusp alfa - EMD Serono/GlaxoSmithKline/Merck KGaAAnti-PD-L1/TGFbetaRII-fusion-proteinMSB-0011359CGSK-4045154M-7824
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTransforming growth factor beta 1 inhibitorsTransforming growth factor beta 2 inhibitorsProgrammed death-ligand 1 blockers
TargetsTransforming growth factor beta 2Programmed death-ligand 1Transforming growth factor beta 1
Therapy Area/IndicationsRespiratory papillomatosisBrain metastasesMetastatic breast cancer +[52] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, GermanyInstitut BergoniéEmd Serono Research & Development Institute Inc +[13] 
Inactive CompaniesGlaxosmithkline PlcAio-Studien-GgmbhMerck Serono Gmbh +[4] 
Active IndicationsRespiratory papillomatosisSolid tumoursThymic epithelial tumor +[37] 
Inactive IndicationsBrain metastasesMetastatic breast cancerSkin Melanoma +[15] 

Other Information

ATC CodeN/A
Related LinksN/A